Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs XPO Inc. Common Stock (XPO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs XPO Inc. Common Stock — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while XPO Inc. Common Stock trades at $187.74 (market cap $21.21B). The key difference: XPO Inc. Common Stock is far larger — about 21.8× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and XPO Inc. Common Stock is more actively traded (663,957 versus 4,325,710). Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and XPO Inc. Common Stock for 6 Days on average.
| MRVI | XPO | |
|---|---|---|
Market Cap | $972.90M | $21.21B |
Volume | 4,325,710 | 663,957 |
Sector | Health | Industrials |
52-Week High | $9.00 | $228.37 |
52-Week Low | $2.83 | $123.66 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $1.08B | $24.90B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
XPO trades at $181.15, up 0.35% today, with a bearish technical signal from moving averages but neutral oscillators. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $8.6B in 2026, and net income margin improved to 4.71%. Recent news highlights operational expansions and industry recognition, such as new service centers and a FreightTech 100 award.
The outlook is positive with strong analyst support—71.9% recommend Buy and a consensus price target of $227.64 implies ~26% upside. Key risks include high valuation multiples (P/E 53.44) and exposure to freight market volatility. Earnings growth and margin improvements are primary catalysts, but investors should monitor competitive pressures and economic cycles.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About XPO Inc. Common Stock
XPO provides freight transportation services in North America and Europe. Its operations include less-than-truckload freight transportation and brokerage services supported by a technology platform.
Read more on XPO →
